ClinicalTrials.gg
TerminatedNCT05502224Updated Oct 26, 2026

Multidisciplinary Approach to Fatigue

An interventional study of Ergospirometry in Breast Cancer and Germ Cell Tumor, sponsored by Jules Bordet Institute. Terminated at 1 site in Belgium. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Jules Bordet Institute · Not applicable, Interventional, and Supportive care

How we know

Why this study was terminated
Poor Accrual
Updated Oct 26, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Breast Neoplasms by Jules Bordet Institute — 7 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Jules Bordet Institute.

Enrollment
31st of 38
12 · median 49
Started
2022
with 2 others
No phase
6 of 42
3 open now
Registered
36th of 42
by date

Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, this one is the 31st largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2022, is one of 6 with no phase, and was the 36th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 42 studies in Breast Neoplasms by Jules Bordet Institute are open now, in 10 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Breast Neoplasms by Jules Bordet Institute, or all of them as a file.
02

Study summary

Prospective longitudinal, single-center, non-randomized study for the implementation of an integrated multidisciplinary fatigue follow-up for young patients with breast cancer or germ cell tumour

Read the detailed description

Each patient will receive a full evaluation by a multidisciplinary evaluation by a multidisciplinary team during one day. This evaluation will take place between 1 and 3 months after the end of "acute" treatments. The team is composed of an oncologist, a psychologist, a physiotherapist, a dietician and a nurse-coach. The goal of this comprehensive evaluation is to :

  • to detect organic or psychological factors (severe depression,...) contributing to fatigue.
  • to evaluate in detail the impact of fatigue on the patient's daily life.
  • to evaluate the patient's level of physical activity in order to propose an adequate and and personalized management. During this evaluation, the patient will be asked to discuss which aspects of his or her daily life he or she would like to improve as a priority. At the end of this complete evaluation, each patient's case will be will be discussed in a multidisciplinary meeting with all the people involved in the program in order to propose a detailed and personalized treatment plan.

This plan will be explained in detail to the patient by the nurse-coach who will organize and coordinate the patient's care. The patient will receive the detailed management plan in writing.

The patient will receive the detailed management plan in writing, which will also be communicated to the patient's treating physicians.

03

Conditions studied

  • Breast Cancer
  • Germ Cell Tumor
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 39 years at the time of signing the
  • Patient who speaks and understands French
  • Signed study informed consent form obtained prior to any study related procedures
  • At minimum, a moderate (>3) fatigue level according to the Standard Rating Scale (NRS) 1 month after completion of acute treatment; as measured at the Survivorship of the standard program
  • Patient with either: curative breast cancer (AJCC stage I-II-III) or a germ cell tumor

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
  • Patient having chosen to participate in another psychosocial intervention study for the duration of the study.
  • Patients with AJCC stage IV breast cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Other
    Specific fatigue management program

    Other: Ergospirometry

Interventions

  • OtherErgospirometry

    Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ

06

What researchers measure

Primary outcomes

  1. Evaluate the feasibility of the specific fatigue management program

    Rate of participation The program will be considered feasible for a given patient if he/she participates in a minimum of 70% of the 70% of the sessions/activities defined in their particular program

    Time frame: Through study completion, an average of 4 years

Secondary outcomes

  1. The measurement of the evolution of the intensity of residual fatigue in the months following acute cancer treatment(s) before and after the specific fatigue management program

    Numerical Rating Scale (NRS) for fatigue

    Time frame: At the time of multidisciplinary screening and at 1, 3, 6, 12 and 18 months after completion of the specific fatigue management program.

07

Study locations

1 site
  • Institut Jules Bordet
    Brussels, 1070, Belgium
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2022 to primary completion in Nov 2025, 39 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Sep 2026 → Nov 2025 and completion Sep 2027 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2022
First posted
Aug 16, 2022
StartActual
Aug 19, 2022
Primary completionActual
Nov 25, 2025was Sep 2026
CompletionActual
Nov 25, 2025was Sep 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Poor Accrual
changed Oct 26, 2026
Primary completion
Sep 2026→Nov 25, 2025 (actual)
Oct 26, 2026
Study completion
Sep 2027→Nov 25, 2025 (actual)
Oct 26, 2026
Enrollment
50 (estimated)→12 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Terminated
    Why stopped Poor Accrual
    Primary completion Sep 2026→Nov 25, 2025 (now actual)
    Study completion Sep 2027→Nov 25, 2025 (now actual)
    Enrollment 50 (estimated)→12 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05502224
Responsible party
Sponsor
First posted
Aug 16, 2022
Start date
Aug 19, 2022
Primary completion
Nov 25, 2025
Completion
Nov 25, 2025
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion